Drug intelligence / Profile preview

Loprecough

Development stage: Unknown
Lead developer: Atco Pharma
Modality: Small Molecules
Administration: Oral

Overview

**Loprecough** is an oral fixed-dose cough syrup marketed by ATCO Pharma containing acetylcysteine 100 mg/5 mL and chlorpheniramine maleate equivalent to chlorpheniramine 2 mg/5 mL. Acetylcysteine is a mucolytic that reduces the viscosity of respiratory mucus, while chlorpheniramine is a first-generation histamine H1-receptor antagonist that helps relieve allergy-associated upper-respiratory symptoms. The product is indicated for productive cough.

Brand names: Loprecough
Other names: لوبريكوف

Targets

HRH1 (Histamine H1 Receptor)

Beyond the preview

Go deeper on Loprecough.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Loprecough.

Explore the full profile